Objective: To analyze the clinical application of transrectal ultrasound guided prostate biopsy. Method: 100 suspected prostate cancer patients admitted to our hospital from January 2019 to January 2021 were selected and underwent transrectal ultrasound guided prostate biopsy. Based on the pathological results of the surgery, the disease detection rate (such as benign prostatic hyperplasia, prostatic intraepithelial tumor, prostate cancer, atypical adenomatous hyperplasia, etc.), visual analogue scale (VAS) scores, and Complication rate (hematuria, urinary retention, fever, vasovagal reflex, etc.), diagnostic efficacy (sensitivity, specificity, diagnostic coincidence rate, misdiagnosis rate, missed diagnosis rate, negative predictive value, positive predictive value). Result: According to the surgical and pathological results, there were 33 cases of benign prostatic hyperplasia, 11 cases of prostatic intraepithelial tumors, 7 cases of prostate cancer, and 17 cases of atypical adenomatous hyperplasia. The patients undergoing transrectal ultrasound guided prostate biopsy included 33 cases of benign prostatic hyperplasia, 11 cases of prostatic intraepithelial tumors, 7 cases of prostate cancer, and 7 cases of atypical adenomatous hyperplasia, with a disease detection rate of 98% (98/100); The patient's VAS score is (2.13 ± 0.45) points, and the incidence of complications is 3% (3/100); The sensitivity of transrectal ultrasound guided prostate biopsy was 92.50% (30/33), specificity was 90.47% (57/63), diagnostic accuracy was 94% (94/100), misdiagnosis rate was 3.17% (2/63), missed diagnosis rate was 9.09% (3/33), negative predictive value was 95% (67/70), and positive predictive value was 92.85% (26/28). Conclusion Transrectal ultrasound-guided prostate biopsy for prostate cancer has high diagnostic accuracy, low incidence of complications such as hematuria and urinary retention, light pain and high application value
